345 results on '"Wish, Jay B."'
Search Results
2. Management of Anemia in Peritoneal Dialysis Patients
3. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
4. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
5. Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
6. Past, Present, and Future of Phosphate Management
7. Iron Deficiency in CKD Without Concomitant Anemia
8. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
9. Management of Anemia in Peritoneal Dialysis Patients
10. What is the impact of anemia pharmacotherapy on chronic kidney disease progression?
11. Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
12. Care Technician Staffing Ratios in Dialysis Units: In Search of a Balance Between Workforce and Patient Safety
13. Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
14. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
15. Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
16. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease
17. Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
18. Erythropoietin and Its Cardiovascular Effects
19. Leading the Dialysis Unit: Role of the Medical Director
20. Anemia in chronic kidney disease
21. Contributors
22. Online Medical Education Significantly Improves Nephrologists’ Knowledge and Confidence for Intravenous (IV) Iron Use in Patients with Iron-Deficiency Anemia (IDA) in CKD: PUB021
23. Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
24. Management of the Hemodialysis Unit: Core Curriculum 2016
25. Anemia and Other Hematologic Complications of Chronic Kidney Disease
26. Contributors
27. 65 - Quality, Safety, Accountability, and Medical Director Responsibilities
28. Chapter 55 - Anemia and Other Hematologic Complications of Chronic Kidney Disease
29. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease
30. Quality, Safety, Accountability, and Medical Director Responsibilities
31. Contributors
32. Kidney disease and congenital heart disease: Partnership for life
33. Moving Beyond the Assumed: Improving Fistula Success Rates
34. What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron
35. Systemic Barriers to Optimal Hemodialysis Access
36. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review
37. After 2 years, the ESRD Treatment Choices model is - surprise - a bust.
38. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON
39. Anemia in renal disease: Diagnosis and management
40. Untangling the Association between Anemia Treatment and Stroke Risk in CKD
41. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation
42. Past, Present, and Future of Chronic Kidney Disease Anemia Management in the United States
43. Dialysis Delivery in Canada and the United States: A View From the Trenches
44. Contributors
45. Anemia and Other Hematologic Complications of Chronic Kidney Disease
46. Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
47. Dialysis Center Productivity Accelerated after 2011 Payment Reform without Compromising Quality of Care
48. Dialysis Technician Burnout: An Opportunity for Empowerment
49. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies
50. Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.